»
News Topics
»
News Archives
»
Pharmaceuticals News
- 12/21/2010
FDA extends Nuvigil jet lag review by 3 months
- 12/21/2010
Eli Lilly, Incyte sign drug development deal
- 12/18/2010
Morning-after pill in Austria prescription-free
- 12/18/2010
Celgene's Revlimid meets cancer study goal
- 12/14/2010
Cubist Pharmaceuticals pays $92.5M for Calixa
- 12/9/2010
Ahead of the Bell: BioMarin Pharma upgraded
- 12/9/2010
BioCryst elects ex-Glaxo and Squibb exec to board
- 12/9/2010
Drug-import backers worry Obama may scuttle plan
- 12/7/2010
Judge in Ohio rejects stay in 1st 1-drug execution
- 12/7/2010
Amgen approves $5 billion stock buyback
- 12/7/2010
Celgene buying Gloucester Pharma for $640 million
- 12/7/2010
Drugmakers' support for health overhaul tested
- 12/4/2010
Watson challenges Takeda's Rozerem patent
- 12/3/2010
Targacept, Astrazeneca cooperate on depression med
- 12/2/2010
Vertex Pharma plans to sell 10M additional shares
- 12/2/2010
Watson completes $1.75 billion buyout of Arrow
- 12/2/2010
CytRx: FDA lifts 2-year hold on arimoclomol tests
- 12/2/2010
Simcere suspends production at Yanshen unit
- 12/2/2010
Hemispherx gets FDA denial on Ampligen treatment
- 5/5/2010
Ahead of the Bell: InterMune plunges on drug delay
- 4/29/2010
Bristol-Myers sees big jumps in Q1 sales, profit
- 4/29/2010
AstraZeneca 1st quarter profit up 29 percent
- 4/29/2010
Sanofi-Aventis 1st quarter profit up 8.6 percent
- 4/27/2010
Court says Vioxx lawsuits can proceed
- 4/27/2010
Novo Nordisk Q1 profit up 23 pct, lifts outlook
- 4/23/2010
Astra drug wins EU approval for depression use
- 4/23/2010
African business takes on malaria
- 4/23/2010
Novartis: EU approves Diovan for children
- 4/21/2010
Merck inks deal on tetanus, diphtheria vaccine
- 4/21/2010
Abbott Labs 1Q profit falls 30 pct, revenue climbs
- 4/20/2010
Price controls expected to slow drug sales in 2010
- 4/19/2010
Javelin Pharmaceuticals ends deal with Myriad
- 4/19/2010
Lilly 1Q profit falls 5 pct in part on reform cost
- 4/15/2010
Roche says first quarter sales up 6 percent
- 4/9/2010
Tengion prices IPO below expected range
- 4/2/2010
FAA: Pilots allowed to take antidepressants on job
- 3/31/2010
Pfizer gave docs $35 million in last half of 2009
- 3/31/2010
GSK receives EU approval for prostate drug
- 3/26/2010
Cuba to vaccinate more than 1.1M against swine flu
- 3/26/2010
K-V Pharma won't resume shipping until 4Q or later
- 3/24/2010
Genzyme faces FDA enforcement over plant issues
- 3/16/2010
IMS: China to be 3rd largest pharma market in 2011
- 3/15/2010
BioSante cancer vaccine gets 'orphan drug' status
- 3/15/2010
FDA asks for risk plan info on diabetes drug
- 3/12/2010
AVEO Pharmaceuticals IPO prices below expectations
- 3/12/2010
Eisai says FDA approved new Dacogen dosing
- 3/11/2010
Pfizer says Sutent fails in breast cancer studies
- 3/11/2010
Watson says FDA approves 6-month dose Trelstar
- 3/11/2010
Astra boosts generic exposure with Torrent deal
- 3/9/2010
Generic drugmaker Teva names Frost as chairman
- 3/9/2010
WuXi PharmaTech moves to 4th-quarter profit
- 3/9/2010
Merck, Sanofi combining animal medicine businesses
- 3/8/2010
ImmunoGen cancer drug gets 'orphan drug' status
- 3/8/2010
ISTA says FDA to review eye drug by Oct. 16
- 3/8/2010
Acura, King cite positive study on pain drug
- 3/8/2010
Drug industry pays for Mo. cold medicine database
- 3/8/2010
Roche suspends arthritis drug study after deaths
- 3/8/2010
Astra's colon cancer drug fails test
- 3/8/2010
Court will hear case about vaccine side effects
- 3/5/2010
WHO: 85 million African children to get polio shot
- 3/4/2010
Bristol-Myers post-Plavix outlook exceeds views
- 3/4/2010
Inspire posts smaller loss as Azasite sales rise
- 3/3/2010
Nektar shares rise as analysts looks to pipeline
- 3/3/2010
Pfizer Alzheimer's disease drug fails in study
- 3/3/2010
Bristol-Myers, Allergan in $413M pain drug deal
- 3/3/2010
Pfizer Alzheimer's disease drug fails in study
- 3/2/2010
Astellas launches OSI takeover bid, legal action
- 3/1/2010
Astellas Pharma plans $3.5B takeover bid for OSI
- 2/25/2010
Obama open to curbing medical malpractice suits
- 2/25/2010
Ahead of the Bell: Anadys hepatitis C drug
- 2/25/2010
Glaxo defends handling of Avandia heart risks
- 2/24/2010
Pfizer says FDA OKs updated infection vaccine
- 2/24/2010
Glaxo defends handling of Avandia heart risks
- 2/23/2010
FDA warns of heart risk with HIV drug combination
- 2/23/2010
Merck makes 4th quarter net profit of $78 million
- 2/22/2010
Novartis gets US approval for meningitis vaccine
- 2/19/2010
J&J partner says EU rejecting skin infection drug
- 2/19/2010
Novartis leukemia drug gets faster FDA review
- 2/19/2010
J&J partner says EU rejecting skin infection drug
- 2/19/2010
Novartis leukemia drug gets faster FDA review
- 2/19/2010
Novavax presents swine flu vaccine data
- 2/19/2010
United Therapeutics pulls Tyvaso application
- 2/18/2010
Regeneron, Bayer eye drug meet study goal
- 2/16/2010
FDA asks Amgen, J&J to discuss anemia drug risks
- 2/16/2010
Schering-Plough purchase hikes Merck sales, profit
- 2/16/2010
Teva Pharmaceutical reports 4th-quarter profit
- 2/12/2010
Curis receives $8 million payment from Debiopharm
- 2/10/2010
Irish drugmaker Elan records Q4 loss, sees rebound
- 2/10/2010
Sanofi-Aventis Q4 profit up on swine flu vaccines
- 2/9/2010
Sanofi-Aventis completes tender offer for Chattem
- 2/8/2010
CVS Caremark 4Q profit grows 11 percent
- 2/8/2010
Michael Jackson doctor charged in singer's death
- 2/5/2010
Teva Pharma settles some Medicaid drug price suits
- 2/4/2010
GlaxoSmithKline Q4 profit up 66 pct
- 2/4/2010
Miss. settles Zyprexa suit for more than $18M
- 2/4/2010
GlaxoSmithKline Q4 profit up 66 pct
- 2/3/2010
Keryx, FDA agree on colon cancer drug study goals
- 2/3/2010
Roche 2009 profit down 22 pct on Genentech costs
- 2/3/2010
Vertex sees positive data in cystic fibrosis study
- 2/3/2010
Auxilium says FDA approved hand drug Xiaflex
© 2009 by Ball & Roberts. All rights reserved. Disclaimer |
Site Map
This attorney website is a public resource for general information about our firm. The content of this site should not be construed as legal advice.
The experienced and respected California trial lawyers at the Pasadena law firm of Ball & Roberts represent clients throughout Southern California in communities such as Los Angeles, Glendale, Burbank, Van Nuys, Santa Monica, Beverly Hills, Long Beach, Brentwood, Hollywood, Malibu, Santa Ana, Hollister, L.A. County, Riverside County, San Bernardino County, Orange County, Ventura County and San Diego County, as well as SoCal regions such as the San Gabriel Valley, San Fernando Valley and the Inland Empire.
This attorney website is a public resource for general information about our firm. The content of this site should not be construed as legal advice.
The experienced and respected California trial lawyers at the Pasadena law firm of Ball & Roberts represent clients throughout Southern California in communities such as Los Angeles, Glendale, Burbank, Van Nuys, Santa Monica, Beverly Hills, Long Beach, Brentwood, Hollywood, Malibu, Santa Ana, Hollister, L.A. County, Riverside County, San Bernardino County, Orange County, Ventura County and San Diego County, as well as SoCal regions such as the San Gabriel Valley, San Fernando Valley and the Inland Empire.
web site by Moncur Associates |
 |